- Home
- COE vs GLSI Comparison
COE vs GLSI Comparison
Compare COE & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- GLSI
- Stock Information
- Founded
- COE 2011
- GLSI 2006
- Country
- COE Singapore
- GLSI United States
- Employees
- COE N/A
- GLSI N/A
- Industry
- COE Other Consumer Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- GLSI Health Care
- Exchange
- COE Nasdaq
- GLSI Nasdaq
- Market Cap
- COE 117.5M
- GLSI 133.4M
- IPO Year
- COE 2016
- GLSI 2020
- Fundamental
- Price
- COE $29.67
- GLSI $8.90
- Analyst Decision
- COE
- GLSI Strong Buy
- Analyst Count
- COE 0
- GLSI 1
- Target Price
- COE N/A
- GLSI $39.00
- AVG Volume (30 Days)
- COE 20.4K
- GLSI 33.7K
- Earning Date
- COE 06-09-2025
- GLSI 08-13-2025
- Dividend Yield
- COE N/A
- GLSI N/A
- EPS Growth
- COE N/A
- GLSI N/A
- EPS
- COE N/A
- GLSI N/A
- Revenue
- COE $59,490,000.00
- GLSI N/A
- Revenue This Year
- COE N/A
- GLSI N/A
- Revenue Next Year
- COE N/A
- GLSI N/A
- P/E Ratio
- COE N/A
- GLSI N/A
- Revenue Growth
- COE 91.87
- GLSI N/A
- 52 Week Low
- COE $9.33
- GLSI $8.06
- 52 Week High
- COE $31.96
- GLSI $18.15
- Technical
- Relative Strength Index (RSI)
- COE 72.86
- GLSI 35.87
- Support Level
- COE $25.75
- GLSI $9.40
- Resistance Level
- COE $29.88
- GLSI $9.92
- Average True Range (ATR)
- COE 2.29
- GLSI 0.29
- MACD
- COE 0.35
- GLSI -0.07
- Stochastic Oscillator
- COE 75.66
- GLSI 0.00
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.